entertainment -WSS

entertainment

author：knowledge 2025-08-12 08:30:06 - browse：86

Christopher Boerner -- biotech JPM coverage from STAT — Bristol CEO Christopher Boerner Business Wire via AP

SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two months. But in trying to sell the company to investors on Monday at the annual J.P. Morgan Healthcare Conference, he pointed to the company’s 150-year history.

He spoke of the “next chapter” for BMS, which saw its stock fall 27% last year, and said that the company would be going through a “period of renewal.” Basically, the tide comes in, but it also goes out. Patents on big-selling medicines expire, but new medicines will come to take their place.

Investors may not be able to view those changes with equanimity. Sales of Bristol’s top sellers will decline significantly or vanish as generic or biosimilar medicines emerge. That includes Eliquis, the blood thinner for stroke prevention that will be one of the first medications subject to price negotiation under the Inflation Reduction Act; Revlimid, the best-selling multiple myeloma medicine that Bristol acquired when it bought Celgene for $74 billion in 2019; and Opdivo, Bristol’s pioneering cancer immunotherapy, which is an $8 billion seller.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： With competition flaring, obesity drug hits goal in liver disease study

Wikipedia

WSS

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Community Health Systems hospitals under DOJ investigation

‘Oppenheimer’ and the risks of AI in health care

Dario to buy mental health app maker Twill in cash and stock deal

Community Health Systems hospitals under DOJ investigation

PBM reform efforts get punted in Congress

leisure time

entertainment

entertainment

Guidelines to prevent youth baseball injuries need more muscle

Wildfire pollution widens asthma inequities on Long Island

Alkermes shareholders re

In utero gene editing: an explainer

Wildfire smoke exposes gaps in outdoor worker protections

What to expect as Trump is arraigned on his Jan 6. indictment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Why palliative psychiatry is worth discussing

Walensky prepares to leave CDC — and Congress — behind

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

hotspot

STAT readers on older presidents, polypills, Medicare, and more

EQRx, failed developer of low

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

New documents shed light on MD Anderson Cancer Institute feud

What to expect as Trump is arraigned on his Jan 6. indictment

Physician groups backed by private equity giant lobby on mergers

knowledge

Wikipedia

hotspot

leisure time